SCHEMBL2365611

SCHEMBL2365611

O=C(O)c1cccc(Oc2ncc(Cl)cc2Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.63
IP6K1 Q92551 2/20 0.63
IP6K3 Q96PC2 2/20 0.63
IP6K2 Q9UHH9 2/20 0.63
CCR2 P41597 1/20 0.61
MRGPRX4 Q96LA9 1/20 0.60
LMNA P02545 1/20 0.58
CYP2C9 P11712 1/20 0.58
TSHR P16473 1/20 0.58
APEX1 P27695 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
KMO O15229 1/20 0.57
MAPK1 P28482 1/20 0.55
AKR1C3 P42330 1/20 0.54
NR4A2 P43354 4/20 0.53
NR4A1 P22736 1/20 0.53
NR4A3 Q92570 1/20 0.53
LIPE Q05469 2/20 0.52
PTGER4 P35408 2/20 0.51
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365692 0.85 L3MBTL1 (0.56) PPARGIP6K1IP6K3IP6K2CCR2
SCHEMBL13366027 0.84 NR1H2 (0.53) PPARGIP6K1IP6K3IP6K2CCR2
SCHEMBL10985263 0.83 RAB9A (0.70) MRGPRX4LMNASMN1; SMN2KMONR4A2
SCHEMBL3506717 0.82 KDM4E (0.60) PPARGIP6K1IP6K3IP6K2CCR2
SCHEMBL9384901 0.81 AKR1C3 (0.58) PPARGCCR2MRGPRX4KMOAKR1C3
SCHEMBL11307569 0.80 MAPK1 (0.69) PPARGIP6K1IP6K3IP6K2CCR2
SCHEMBL1168418 0.79 PPARG (0.62) PPARGCCR2MRGPRX4KMOAKR1C3
SCHEMBL25989724 0.79 IP6K1 (1.00) PPARGIP6K1IP6K3IP6K2NPC1
SCHEMBL4910658 0.77 CCR2 (1.00) CCR2CYP2C9
SCHEMBL10818017 0.77 TTR (0.61) IP6K1IP6K3IP6K2MRGPRX4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927549-B2 Adamantyl benzamide derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2015-01-06 US disclosed
US-20110224244-A1 Adamantyl Benzamide Derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2011-09-15 US disclosed
EP-2362730-A1 ADAMANTYL BENZAMIDE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2011-09-07 EP disclosed
WO-2010059618-A1 ADAMANTYL BENZAMIDE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224244-A1 Adamantyl Benzamide Derivatives HSD11B1, HSD17B11, HSD3B1 PPARG 1286/4885IP6K1 3535/4885IP6K3 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.